Skip to content

United Therapeutics

US · UTHR #836 by market cap Listed 1970
554.73 -4.37 -0.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 4 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.6 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
104.35% -0.59pp
Institutions
1,044 -4
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund70.75%
Hedge Fund22.67%
Government Pension Fund3.12%
Public Company2.77%
Individual/Insider1.97%
Sovereign Wealth Fund1.72%
Private Company1.44%
VC/PE Fund0.99%
Insurance Company0.32%

Top holders as of 2026-09-30

BlackRock 13.09% · 5.58M sh
Avoro Capital Advisors LLC 6.47% · 2.76M sh
Vanguard Capital Management, LLC 5.17% · 2.20M sh
State Street Global Advisors 4.58% · 1.95M sh
Vanguard Portfolio Management, LLC 4.49% · 1.91M sh
Wellington Management Group 4.46% · 1.90M sh
Renaissance Technologies Corp. 3.94% · 1.68M sh
Amundi Asset Management 2.32% · 988.93K sh
Janus Henderson Group plc 1.94% · 831.13K sh
Geode Capital Management, LLC 2.29% · 974.99K sh
Citadel Advisors LLC 2.18% · 928.46K sh
Norges Bank Investment Management 1.62% · 694.75K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 0 buys · 50 sells

NameRoleStake
Martine Rothblatt Chairperson & CEO 1.57%
Paul Mahon General Counsel 0.11%
Thomas Thompson Independent Director 0.05%
Richard Giltner Independent Director 0.05%
Michael Benkowitz President 0.05%
James Edgemond Chief Financial Officer 0.04%
Raymond Kurzweil Independent Director 0.03%
Nilda Mesa Independent Director 0.01%
Judy Olian Independent Director 0.01%
Louis Sullivan Independent Director & Member of the Scientific Advisory Board 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-11 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–597.33
2026-11-08 Christopher Patusky Independent Vice Chairman & Lead Independent Director Derivative Exercise and Sale -1,210 $132.30–580.00
2026-11-05 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–568.68
2026-11-04 Paul Mahon General Counsel Derivative Exercise and Sale -8,300 $146.03–602.72
2026-11-02 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–605.97
2026-11-01 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–598.84
2026-10-29 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–608.05
2026-10-28 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–599.30
2026-10-27 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–588.39
2026-10-26 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–592.84
2026-10-25 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–592.92
2026-10-22 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–588.00
2026-10-21 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–590.40
2026-10-20 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–566.43
2026-10-19 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–563.56
2026-10-18 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–556.88
2026-10-15 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–543.85
2026-10-14 Martine Rothblatt Chairperson & CEO Derivative Exercise and Sale -9,500 $117.76–551.50
2026-10-14 Paul Mahon General Counsel Intent to Sell (Form 144) -8,300 $544.30
2026-10-14 Paul Mahon General Counsel Derivative Exercise and Sale -8,300 $146.03–546.56

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

United Therapeutics discussion 0 comments

Add a comment